Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis.

Souza TM, Salluh JI, Bozza FA, Mesquita M, Soares M, Motta FC, Pitrowsky MT, de Lourdes Oliveira M, Mishin VP, Gubareva LV, Whitney A, Rocco SA, Gonçalves VM, Marques VP, Velasco E, Siqueira MM.

PLoS One. 2010 Nov 30;5(11):e14158. doi: 10.1371/journal.pone.0014158.

2.

Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days.

Ryoo SM, Kim WY, Sohn CH, Seo DW, Oh BJ, Lee JH, Lee YS, Lim KS.

Influenza Other Respir Viruses. 2013 Sep;7(5):833-7. doi: 10.1111/irv.12065. Epub 2012 Dec 26.

3.

Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.

Ling LM, Chow AL, Lye DC, Tan AS, Krishnan P, Cui L, Win NN, Chan M, Lim PL, Lee CC, Leo YS.

Clin Infect Dis. 2010 Apr 1;50(7):963-9. doi: 10.1086/651083.

PMID:
20180701
4.

Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation.

Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Iwakuni O, Egashira K, Yamaji K, Kashiwagi S.

J Infect Chemother. 2012 Apr;18(2):180-6. doi: 10.1007/s10156-011-0314-2. Epub 2011 Dec 23.

PMID:
22193710
5.

Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010.

Malato L, Llavador V, Marmier E, Youssef J, Balick Weber C, Rozé H, Bessede E, Fleury HJ.

Euro Surveill. 2011 Jan 27;16(4). pii: 19776.

6.

Duration of viral shedding in hospitalized patients infected with pandemic H1N1.

Meschi S, Selleri M, Lalle E, Bordi L, Valli MB, Ferraro F, Ippolito G, Petrosillo N, Lauria FN, Capobianchi MR.

BMC Infect Dis. 2011 May 23;11:140. doi: 10.1186/1471-2334-11-140.

7.

Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.

Meijer A, Jonges M, Abbink F, Ang W, van Beek J, Beersma M, Bloembergen P, Boucher C, Claas E, Donker G, van Gageldonk-Lafeber R, Isken L, de Jong A, Kroes A, Leenders S, van der Lubben M, Mascini E, Niesters B, Oosterheert JJ, Osterhaus A, Riesmeijer R, Riezebos-Brilman A, Schutten M, Sebens F, Stelma F, Swaan C, Timen A, van 't Veen A, van der Vries E, te Wierik M, Koopmans M.

Antiviral Res. 2011 Oct;92(1):81-9. doi: 10.1016/j.antiviral.2011.07.004. Epub 2011 Jul 13.

PMID:
21767571
8.

Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS).

Fraaij PL, Schutten M, Javouhey E, Burleigh L, Outlaw R, Kumar D, Boucher CA.

Antivir Ther. 2015;20(6):633-42. doi: 10.3851/IMP2957. Epub 2015 Apr 7.

PMID:
25849228
9.

Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.

Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, Liang ZA, Liang L, Zhang SJ, Zhang B, Gu L, Lu LH, Wang DY, Wang C; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China.

N Engl J Med. 2009 Dec 24;361(26):2507-17. doi: 10.1056/NEJMoa0906612. Epub 2009 Dec 9.

11.

Pandemic H1N1 illness prognosis: evidence from clinical and epidemiological data from the first pandemic wave in São Paulo, Brazil.

Bellei NC, Cabeça TK, Carraro E, Goto JM, Cuba GT, Hidalgo SR, Burattini MN.

Clinics (Sao Paulo). 2013 Jun;68(6):840-5. doi: 10.6061/clinics/2013(06)19.

12.

Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.

Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, Guo X, Zheng Y, van Doorn HR, Farrar J, Gao Z, Feng Z, Wang Y, Yang W.

BMJ. 2010 Sep 28;341:c4779. doi: 10.1136/bmj.c4779.

13.

Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients.

Giannella M, Alonso M, Garcia de Viedma D, Lopez Roa P, Catalán P, Padilla B, Muñoz P, Bouza E.

Clin Microbiol Infect. 2011 Aug;17(8):1160-5. doi: 10.1111/j.1469-0691.2010.03399.x. Epub 2010 Dec 3.

14.

Critically ill children with pandemic influenza (H1N1) in pediatric intensive care units in Turkey.

Kendirli T, Demirkol D, Yildizdas D, Anil AB, Asilioğlu N, Karapinar B, Erkek N, Sevketoğlu E, Dursun O, Arslanköylü AE, Bayrakçi B, Bosnak M, Köroğlu T, Horoz OO, Citak A, Kesici S, Ates C, Karaböcüoğlu M, Ince E.

Pediatr Crit Care Med. 2012 Jan;13(1):e11-7. doi: 10.1097/PCC.0b013e31820aba37.

PMID:
21263368
15.

Duration of viral shedding of influenza A (H1N1) virus infection treated with oseltamivir and/or traditional Chinese medicine in China: a retrospective analysis.

Wang YG, Jiang M, Wang RB, Zha QL, Zhang SJ, Zhou GQ, Li XW, Wang YY, Lv AP.

J Tradit Chin Med. 2012 Jun;32(2):148-55.

16.

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.

Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA.

Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22.

PMID:
24268590
17.

Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico.

Higuera Iglesias AL, Kudo K, Manabe T, Corcho Berdugo AE, Corrales Baeza A, Alfaro Ramos L, Guevara Gutiérrez R, Manjarrez Zavala ME, Takasaki J, Izumi S, Bautista E, Perez Padilla JR.

PLoS One. 2011;6(7):e21838. doi: 10.1371/journal.pone.0021838. Epub 2011 Jul 8.

18.

Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.

Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp M, Gaillard S, Duval X, Blanchon T, Leport C, Gueyffier F, Van Der Werf S, Lina B.

Antiviral Res. 2012 Nov;96(2):130-7. doi: 10.1016/j.antiviral.2012.08.002. Epub 2012 Aug 14.

PMID:
22909899
19.

Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.

Rath B, von Kleist M, Tief F, Karsch K, Tuerk E, Muehlhans S, Louis F, Skopnik H, Schweiger B, Duwe S.

Pediatr Infect Dis J. 2012 Sep;31(9):899-905. doi: 10.1097/INF.0b013e31825c7304.

PMID:
22581220
20.

Pandemic influenza A (H1N1) 2009: risk factors for hospitalization.

Lenzi L, Mello ÂM, Silva LR, Grochocki MH, Pontarolo R.

J Bras Pneumol. 2012 Jan-Feb;38(1):57-65. English, Portuguese.

Supplemental Content

Support Center